Drug class
PCSK9-targeting small interfering RNA (siRNA); RNA interference lipid-lowering therapy
Mechanism of action
A GalNAc-conjugated siRNA targets PCSK9 mRNA in hepatocytes and promotes RISC-mediated degradation, reducing PCSK9 protein and increasing hepatic LDL receptor recycling and LDL-cholesterol clearance.
General use cases
- Treatment of adults with hypercholesterolaemia, including heterozygous familial hypercholesterolaemia, as an adjunct to diet and other lipid-lowering therapies under the US LIPIDRA indication (approved 2026); dosing and label-specific eligibility apply
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
